RenovoRx RNXT
NASDAQ RNXT
$1.32 +0.00 (+0.00%)
At close: Aug 21, 2026 · 4:00 PM EDT

RenovoRx (RNXT) Change in Accured Expenses (2020 - 2026)

RenovoRx (RNXT) posted Change in Accured Expenses of -$391000.0 for Q1 2026, down 423.14% sequentially from $121000.0 in Q4 2025, and up 32.59% YoY from -$294902.5 in Q1 2025.

RenovoRx (RNXT) Change in Accured Expenses (2020 - 2026) Analysis & Trends

RenovoRx has reported Change in Accured Expenses for 7 years, with the latest figure at -$391000.0 in Q1 2026.

  • Quarterly Change in Accured Expenses rose 32.59% year-over-year to -$391000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$76000.0 (down 13.43% YoY) and the FY2025 annual result came in at -$265000.0, down 141.67% from the prior year.
  • Change in Accured Expenses fell to -$391000.0 in Q1 2026 per RNXT's latest filing, from $121000.0 in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $428000.0 in Q3 2023 and troughed at -$641000.0 in Q4 2023.
  • A 5-year average of $10647.1 and a median of $103000.0 in 2025 frame the typical range for Change in Accured Expenses.
  • The widest YoY moves for Change in Accured Expenses: up 1396.3% in 2023, down 16125.0% in 2023.
  • Over 5 years, Change in Accured Expenses stood at $4000.0 in 2022, then plunged by 16125.0% to -$641000.0 in 2023, then jumped by 125.59% to $164000.0 in 2024, then slipped by 26.22% to $121000.0 in 2025, then slumped by 423.14% to -$391000.0 in 2026.
  • According to Business Quant data, Change in Accured Expenses over the past three periods registered -$391000.0, $121000.0, and $103000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 222.50 Mn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 492.70 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 11.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 212.44 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 61.62 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 68.82 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 RenovoRx 62.20 Mn 62.20 Mn 766,000.00 163,000.00

Historic Data

Download Data
DateValue
Jun 30, 2026 163,000.00
Jun 30, 2026 163,000.00
Mar 31, 2026 -391,000.00
Mar 31, 2026 -391,000.00
Dec 31, 2025 121,000.00
Dec 31, 2025 121,000.00
Sep 30, 2025 103,000.00
Sep 30, 2025 103,000.00
Jun 30, 2025 91,000.00
Jun 30, 2025 91,000.00
Mar 31, 2025 -580,000.00
Mar 31, 2025 -580,000.00
Dec 31, 2024 164,000.00
Dec 31, 2024 164,000.00
Sep 30, 2024 213,000.00
Sep 30, 2024 213,000.00
Jun 30, 2024 136,000.00
Jun 30, 2024 136,000.00
Mar 31, 2024 123,000.00
Mar 31, 2024 123,000.00